Loading
Cancer that does not respond to a treatment at all, or grows straight through it. Distinct from relapse, where the cancer responded first and came back later.
Refractory disease implies primary resistance: the tumour never depended on the drug's target, could not be reached by it, or had a resistant population from the outset. 'Relapsed or refractory' (R/R) is the standard label for the population in later-line trials, particularly in blood cancers, and 'platinum-refractory' ovarian cancer (progressing during or within a month of platinum chemotherapy) marks the group with the shortest survival. Because refractory patients have exhausted standard options, they are where new mechanisms are first tested and where the bar for approval is lowest.
Shares Lines of therapy, Accelerated approval, Drug resistance (primary and acquired).
Shares Progression, Recurrence and relapse.
Shares Lines of therapy, Accelerated approval.
Shares Accelerated approval, Drug resistance (primary and acquired).
Shares Lines of therapy, Drug resistance (primary and acquired).
Shares Lines of therapy, Accelerated approval.
Shares Progression, Lines of therapy.
Shares Accelerated approval, Drug resistance (primary and acquired).